Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity

[1]  Bill Williams,et al.  Impact on Creatinine Renal Clearance by the Interplay of Multiple Renal Transporters: A Case Study with INCB039110 , 2015, Drug Metabolism and Disposition.

[2]  J. Polli,et al.  Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). , 2013, Toxicology and applied pharmacology.

[3]  G. Gobe,et al.  Carvedilol efficiently protects kidneys without affecting the antitumor efficacy of cisplatin in mice. , 2013, Chemico-biological interactions.

[4]  F. Müller,et al.  Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. , 2013, Biochemical pharmacology.

[5]  H. Kusuhara,et al.  Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin. , 2013, Journal of pharmaceutical sciences.

[6]  A. Gibson,et al.  Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance , 2013, Clinical pharmacology and therapeutics.

[7]  Andrej Sali,et al.  Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. , 2013, Journal of medicinal chemistry.

[8]  A. Rubbert,et al.  Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients , 2013, Infection.

[9]  G. Gobe,et al.  Carvedilol Protects Against Apoptotic Cell Death Induced by Cisplatin in Renal Tubular Epithelial Cells , 2012, Journal of toxicology and environmental health. Part A.

[10]  Jing Zhang,et al.  Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[11]  J. W. Higgins,et al.  Ablation of Both Organic Cation Transporter (Oct)1 and Oct2 Alters Metformin Pharmacokinetics but Has No Effect on Tissue Drug Exposure and Pharmacodynamics , 2012, Drug Metabolism and Disposition.

[12]  Minoru Yoshida,et al.  Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events , 2012, Clinical and Experimental Nephrology.

[13]  H. Kusuhara,et al.  Competitive Inhibition of the Luminal Efflux by Multidrug and Toxin Extrusions, but Not Basolateral Uptake by Organic Cation Transporter 2, Is the Likely Mechanism Underlying the Pharmacokinetic Drug-Drug Interactions Caused by Cimetidine in the Kidney , 2012, Journal of Pharmacology and Experimental Therapeutics.

[14]  Hongbing Wang,et al.  Deficiency of Multidrug and Toxin Extrusion 1 Enhances Renal Accumulation of Paraquat and Deteriorates Kidney Injury in Mice , 2011, Molecular pharmaceutics.

[15]  K. Giacomini,et al.  Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins , 2011, Molecular Cancer Therapeutics.

[16]  A. C. Santos,et al.  Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria. , 2011, Chemico-biological interactions.

[17]  A. Yonezawa,et al.  Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. , 2010, Biochemical pharmacology.

[18]  Jia Yu,et al.  Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. , 2010, Biological & pharmaceutical bulletin.

[19]  D. Gerhold,et al.  Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies , 2010, Nature Biotechnology.

[20]  E. Berns,et al.  Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) , 2010, British journal of pharmacology.

[21]  H. Glaeser,et al.  Interaction of beta‐blockers with the renal uptake transporter OCT2 , 2009, Diabetes, obesity & metabolism.

[22]  A. Sparreboom,et al.  Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin‐Induced Nephrotoxicity , 2009, Clinical pharmacology and therapeutics.

[23]  M. Fielden,et al.  Validation of putative genomic biomarkers of nephrotoxicity in rats. , 2008, Toxicology.

[24]  S. Tohno,et al.  Accumulation of platinum in the intervertebral discs and vertebrae of ovarian tumor-bearing patients treated with cisplatin , 1994, Biological Trace Element Research.

[25]  S. Masuda,et al.  Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. , 2007, Biochemical pharmacology.

[26]  S. Masuda,et al.  Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family) , 2006, Journal of Pharmacology and Experimental Therapeutics.

[27]  O. Ogawa,et al.  Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. , 2006, Journal of the American Society of Nephrology : JASN.

[28]  G. Feuerstein,et al.  Carvedilol case history: the discovery and development of the first β-blocker for the treatment of congestive heart failure , 2006, Expert opinion on drug discovery.

[29]  S. Masuda,et al.  Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. , 2005, Biochemical pharmacology.

[30]  S. Masuda,et al.  Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. , 2005, Drug metabolism and pharmacokinetics.

[31]  M. Okuda,et al.  Creatinine Transport by Basolateral Organic Cation Transporter hOCT2 in the Human Kidney , 2004, Pharmaceutical Research.

[32]  G. Feuerstein,et al.  Pharmacology of Carvedilol: Rationale for Use in Hypertension, Coronary Artery Disease, and Congestive Heart Failure , 1997, Cardiovascular Drugs and Therapy.

[33]  R. Dorr,et al.  Cimetidine enhances cisplatin toxicity in mice , 1988, Journal of Cancer Research and Clinical Oncology.

[34]  A. Schinkel,et al.  Deficiency in the Organic Cation Transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in Mice Abolishes Renal Secretion of Organic Cations , 2003, Molecular and Cellular Biology.

[35]  Hideyuki Saito,et al.  Gene expression levels and immunolocalization of organic ion transporters in the human kidney. , 2002, Journal of the American Society of Nephrology : JASN.

[36]  V. Ganapathy,et al.  Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. , 2000, Biochimica et biophysica acta.

[37]  D. Gründemann,et al.  Selective substrates for non-neuronal monoamine transporters. , 1999, Molecular pharmacology.

[38]  F. Lang,et al.  Cloning and characterization of two human polyspecific organic cation transporters. , 1997, DNA and cell biology.

[39]  Trefor Owen Morgan.  Clinical Pharmacokinetics and Pharmacodynamics of Carvedilol , 1994, Clinical pharmacokinetics.

[40]  H. Spahn‐Langguth,et al.  Carvedilol Stereopharmacokinetics in Rats: Affinities to Blood Constituents and Tissues , 1993, Archiv der Pharmazie.

[41]  N. Mulder,et al.  The protective potential of the combination of verapamil and cimetidine on cisplatin‐induced nephrotoxicity in man , 1987, Cancer.

[42]  J. Harrington,et al.  Platinum nephrotoxicity. , 1978, The American journal of medicine.

[43]  R. McCOY,et al.  Platinum nephrotoxicity , 1974, Cancer.